Journal of gastrointestinal and liver diseases : JGLD最新文献

{"title":"Fecal Microbiome Transplantation for Recurrent CDI: Treatment Efficacy and Safety with Oral Capsules.","authors":"Tadas Urbonas, Dalius Petrauskas, Vytautas Kiudelis, Laimas Jonaitis, Jurgita Skieceviciene, Rolandas Gedgaudas, Edita Kiudeliene, Irena Valantiene, Romanas Zykus, Greta Varkalaite, Ruta Inciuraite, Elzbieta Trapenske, Ugne Kulokiene, Paulius Jonaitis, Rima Ramonaite, Justina Velickiene, Aida Zvirbliene, Egidijus Morkunas, Irma Kuliaviene, Jolanta Sumskiene, Kestutis Adamonis, Andrius Macas, Kristina Kupcinskiene, Laura Lukosiene, Dainius Janciauskas, Lina Poskiene, Astra Vitkauskiene, Gianluca Ianiro, Antonio Gasbarrini, Gediminas Kiudelis, Juozas Kupcinskas","doi":"10.15403/jgld-5990","DOIUrl":"https://doi.org/10.15403/jgld-5990","url":null,"abstract":"<p><strong>Background and aims: </strong>Fecal microbiota transplantation is an effective treatment method for recurrent Clostridioides difficile infection. Widely used enteric tube and colonoscopy methods demonstrate excellent efficacy and safety results. Recent data suggest that new fecal microbiota transplantation methods using oral capsules may provide a less invasive approach. In this study, we aimed to compare primary fecal microbiota transplantation efficacy as well as short- and long-term safety of two different administration routes: oral capsules and enteric tube.</p><p><strong>Methods: </strong>This retrospective study included 60 consecutive patients who underwent fecal microbiota transplantation for recurrent Clostridioides difficile infection. Thirty participants received 50 oral capsules containing frozen material for a single day and 30 patients received fecal microbiota transplantation via nasoenteric tube. All patients received standard treatment with oral vancomycin 500 mg q.i.d. for at least five days before the procedure. After intervention, patients were followed up for at least six months. Data on Clostridioides difficile infection recurrences and health status were collected and analyzed.</p><p><strong>Results: </strong>The oral capsules group consisted of 30 patients. Among them, 22 (73.3%) participants experienced resolution of symptoms after a single fecal microbiota transplantation, while eight (26.7%) patients developed recurrent diarrhea within eight weeks. The other 30 patients received treatment via nasoenteric tube. Among them, 24 (80%) patients were cured after a single fecal microbiota transplantation, while six (20%) experienced recurrent disease within eight weeks. The primary efficacy did not show significant differences between the two groups (p=0.85). Throughout the follow-up period, no serious adverse events or fecal microbiota transplantation related deaths were reported in both groups.</p><p><strong>Conclusions: </strong>Fecal microbiota transplantation with frozen oral capsules is a safe, less invasive method with comparable efficacy to nasoenteric administration route.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"34 2","pages":"199-204"},"PeriodicalIF":0.0,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cannabis Use and Outcomes in Patients with Chronic Pancreatitis: A National Inpatient Sample Analysis.","authors":"Aalam Sohal, Nuhar Thind, Harbir Singh Billing, Humzah Iqbal, Rohan Menon, Vikash Kumar, Aalam Sohal, Juliana Yang","doi":"10.15403/jgld-6066","DOIUrl":"https://doi.org/10.15403/jgld-6066","url":null,"abstract":"<p><strong>Background and aims: </strong>Cannabis is a commonly used recreational and medicinal substance and has been shown to have anti-inflammatory and analgesic effects. Previous studies have shown that cannabis may reduce disease severity of pancreatitis. We aim to use nationally available data to further investigate the impact of cannabis on outcomes among patients with chronic pancreatitis (CP).</p><p><strong>Methods: </strong>Nationwide Inpatient Sample (NIS) 2016-2020 was used to identify patients with CP. Patients were stratified based on the presence of cannabis use. Data was collected regarding patient demographics, comorbidities, and Charlson Comorbidity Index (CCI). The outcomes assessed were sepsis, acute kidney injury (AKI), deep vein thrombosis (DVT), pulmonary embolism (PE), intensive care unit (ICU) admission, acute pancreatitis (AP), pancreatic cancer, total charges, and length of stay. The relationships were analyzed using multivariate logistic regression.</p><p><strong>Results: </strong>Out of 907,790 hospitalized patients in this study; 52,360 (5.8%) were cannabis users. After adjusting for confounding factors, cannabis use was associated with decreased odds of mortality (aOR=0.47, p<0.001), DVT (aOR=0.71, p<0.001), PE (aOR=0.622, p=0.002), ICU admission (aOR=0.705, p<0.001), pancreatic cancer (aOR=0.730, p=0.021). There was no difference in odds of AKI, sepsis or AP between the two groups.</p><p><strong>Conclusions: </strong>Our study found that cannabis use is associated with reduced disease severity and better outcomes among patients hospitalized with CP. Further studies are needed to confirm our findings and explore the role of cannabinoids in pancreatitis.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"34 2","pages":"220-226"},"PeriodicalIF":0.0,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Visualisation of the Ampulla of Vater on Small Bowel Capsule Endoscopy.","authors":"Eliezer Zahra, Rebecca Sammut, Reena Sidhu, Lucia Scaramella, Nicole Sciberras, Kelly Conti, Clelia Marmo, Giulia Scardino, Cristina Carretero, Emmanuele Rondonotti, Maria Elena Riccioni, Luca Elli, Nicoletta Nandi, Pierre Ellul, Stefania Chetcuti Zammit","doi":"10.15403/jgld-5941","DOIUrl":"https://doi.org/10.15403/jgld-5941","url":null,"abstract":"<p><strong>Background and aims: </strong>Visualization of lesions on small bowel capsule endoscopy (SBCE) depends on capsule motility. The aim of this study was to assess the delineation of the ampulla of Vater (AoV) across different levels of expertise and reading speeds.</p><p><strong>Methods: </strong>This was a study whereby de-identified SBCE videos were reviewed by scrolling with mouse wheel and then at a speed of 10 frames per second (10 fps). Data regarding delineation of the AoV and bile was collected.</p><p><strong>Results: </strong>Thirty patients (63.3% males, 63.5 years +/- SD 7.164) were included. The mean detection rate of AoV was higher when the mouse wheel was used than when compared to 10 fps for trainees (35% vs. 21.7%) and experts (33.8% vs 20.5%). The rate of concordance in the delineation of the AoV amongst experts declined with higher reviewing speeds (κ 0.493, p=0.98 mouse wheel vs κ 0.482, p=0.2 10 fps). Experts had a better agreement in detecting AoV than trainees (κ 0.493, p=0.98 vs 0.482, p=0.2 for mouse wheel and 10 fps respectively for experts: κ 0.135, p=0.75 for mouse wheel and 0.109, p=0.2 at 10 fps).</p><p><strong>Conclusions: </strong>This study demonstrates that visualization of the AoV is dependent on the level of expertise and capsule speed.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"34 2","pages":"167-173"},"PeriodicalIF":0.0,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144532002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JGLD under the Aegis of the Romanian Academy.","authors":"Monica Acalovschi","doi":"10.15403/jgld-6360","DOIUrl":"https://doi.org/10.15403/jgld-6360","url":null,"abstract":"","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"34 2","pages":"149"},"PeriodicalIF":0.0,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colovenous Fistula?","authors":"İdris Kurt","doi":"10.15403/jgld-6090","DOIUrl":"https://doi.org/10.15403/jgld-6090","url":null,"abstract":"","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"34 1","pages":"134"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143736272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Constipation and Risk of Acute Myocardial Infarction: A Systematic Review and Meta-Analysis of Cohort Studies.","authors":"Thanathip Suenghataiphorn, Nutchapon Xanthavanij, Panat Yanpiset, Thitiphan Srikulmontri, Ben Thiravetyan, Narisara Tribuddharat, Vitchapong Prasitsumrit, Pojsakorn Danpanichkul, Tulaton Sodsri, Narathorn Kulthamrongsri, Phuuwadith Wattanachayakul","doi":"10.15403/jgld-5852","DOIUrl":"10.15403/jgld-5852","url":null,"abstract":"<p><strong>Background and aims: </strong>Constipation is commonly seen among patients with cardiovascular diseases and is linked to adverse outcomes. However, the association between constipation and the risk of acute myocardial infarction (AMI) remains conflicting. Therefore, we aimed to conduct a systematic review and meta-analysis to summarize the available data on this topic.</p><p><strong>Method: </strong>We identified potentially eligible studies from the MEDLINE and EMBASE databases, searching from inception to May 2024, to investigate the association between constipation and the risk of developing AMI. To be included, studies needed to compare incidence of AMI between cohorts with and without constipation. Effect size and 95% confidence intervals (CIs) were combined using the generic inverse variance method. All statistical analyses were performed by Review Manager 5.4.</p><p><strong>Results: </strong>Our meta-analysis included seven studies that met the eligibility criteria. There were 5,351,976 participants, with a mean age of 57.8 years and 74% were males. We found that patients with constipation had a 14% increased risk of AMI with a pooled risk ratio (RR) of 1.14 (95%CI: 1.08-1.14; I²=85%; p<0.001) compared to those without constipation.</p><p><strong>Conclusions: </strong>Our study revealed that constipation is associated with a higher risk of AMI. Emphasizing and addressing gastrointestinal health, including constipation, as an important issue is essential for comprehensive cardiovascular care.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"34 1","pages":"108-114"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143736274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tattoo ink: Does it really stay in the skin? A potential link between tattoos and leukemia in fatty liver disease patient.","authors":"Abdulrahman Ismaiel, Ioana Rusu, Anca Bojan, Dan L Dumitrascu","doi":"10.15403/jgld-6052","DOIUrl":"https://doi.org/10.15403/jgld-6052","url":null,"abstract":"","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"34 1","pages":"135-137"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143736316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leukocytoclastic vasculitis as a rare adverse effect of ustekinumab in a patient with Crohn's disease.","authors":"Hüseyin Aykut, Baver Ordu, Berkay Dertsiz, Gupse Adalı, Özben Yalçın","doi":"10.15403/jgld-6036","DOIUrl":"https://doi.org/10.15403/jgld-6036","url":null,"abstract":"","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"34 1","pages":"137-138"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143736278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Efficacy of Traditional Chinese Medicine for Crohn's Disease Treatment: A Systematic Review and Meta-Analysis.","authors":"Michael L Chang, Kaitlyn L Mi, Rachel R Cunningham, William A Catterall, Mahlet A Yared, Corey A Siegel, Renata W Yen","doi":"10.15403/jgld-5729","DOIUrl":"10.15403/jgld-5729","url":null,"abstract":"<p><strong>Background and aims: </strong>Crohn's disease (CD) is an inflammatory bowel disease with limited treatment options for patients with mild to moderately active disease. There is a lack of consensus for using traditional Chinese medicine (TCM) for symptom relief. This review aimed to assess the efficacy of TCM compared to placebo for CD symptom severity relief in patients with mild to moderate CD.</p><p><strong>Methods: </strong>We searched MEDLINE via PubMed, the Cochrane Library, Scopus, and CINAHL for articles and reviewed results from Web of Science, Google Scholar, clinicaltrials.gov, and reference lists of included studies. We included randomized control trials comparing TCM to placebo in patients with mild to moderate CD to evaluate change in objective symptom severity [Crohn's Disease Activity Index (CDAI) and Crohn's Disease Endoscopic Index of Severity (CDEIS)]. We imported selected articles for dual blinded review, used random-effects models to calculate the mean CDAI and CDEIS differences between TCM and placebo, and qualitatively analyzed differences in inflammatory biomarkers and quality of life.</p><p><strong>Results: </strong>The search identified 232 relevant studies. We included five studies, totalling 292 participants utilizing acupuncture and herb-partitioned moxibustion. The studies demonstrated a more significant decrease in mean CDAI score due to TCM compared to placebo [-49.91 (95% CI: -64.97, -34.84; p<0.00001); (I2 = 61%, p=0.03)]. Two studies also demonstrated an overall difference in mean CDEIS between TCM and placebo [-2.96 (95% CI: -6.31, 0.40; p=0.08); (I2 = 53%, p=0.140)]. Improvements in quality of life scores were greater in TCM versus placebo groups. There were mixed results for changes in inflammatory biomarkers.</p><p><strong>Conclusion: </strong>Our findings suggest that TCM may improve objective CD symptoms compared to placebo. Additional studies with more extensive and diverse populations are necessary to determine TCM's true effects on CD patients.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"34 1","pages":"98-107"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143736318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colitis Trouble up High: A Case of Gastroduodenal Ulcerative Colitis and Literature Review.","authors":"Suzanne Cauchi, Frederique Van Venetien, Martina Sciberras, Pierre Ellul","doi":"10.15403/jgld-5903","DOIUrl":"10.15403/jgld-5903","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background and aims: &lt;/strong&gt;The presence of backwash ileitis, post-colectomy pre-pouch ileitis, or pouchitis has been widely described in the presentation of ulcerative colitis [UC]. However, over the years, a few cases of upper gastrointestinal [UGI] inflammation in patients with UC have been reported, most commonly post-colectomy.  The aim of this review was to conduct an analysis of the current literature to identify the prevalence, risk factors and current treatment of UGI UC.  Methods: Case report and review of the literature. An electronic search of five bibliographic databases [Pubmed, Cochrane, DOAJ, Science Direct, and JSTOR], was conducted. A combination of keywords and medical subject headings [MeSH] related to \"small intestine\" and \"inflammation\" or \"enteritis\" and \"colectomy\" or \"post operative complications\" or \"ileostomy\" or \"stoma\" and \"ulcerative colitis\" or \"inflammatory bowel disease\" were used. Referenced papers not fully available in English text were excluded from the study.  The manuscripts were analysed for age, gender, extent of colonic and UGI disease, timing of UGI presentation, surgical history, treatment and follow-up.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;We present the case of a 59-year-old woman with diffuse upper gastrointestinal (UGI) ulcerative colitis (UC) that was refractory to steroid treatment, occurring nine years after a panproctocolectomy for medical treatment failure Upon initiation of an anti-TNFɑ [adalimumab], she achieved remission. We then systematically reviewed the literature to analyse previous reports of patients presenting with UGI UC to understand the prevalence and identify risk factors for developing this condition. To date, 43 cases have been published describing UGI UC with a male to female ratio 5:4 with a mean age of 37.52 years [IQ range 27 years] The majority [85.7%] of these patients were post-colectomy secondary to pancolitis. The mean time post-colectomy for UGI UC to occur is 14 months [range 0-12 years]. The prognosis of these patients were generally good; however, severe complications including haemorrhage, perforation and death have been reported. The inflammatory distribution affected the duodenum [74%] &gt; ileum [57%] &gt; jejunum [31%] &gt; stomach [4%]. The majority of patients with reported changes in the stomach had a pangastritis pattern, with only one case describing isolated antral inflammation. No standardised treatment strategy is available, however, intravenous and oral corticosteroids, 5-aminosalicylates, thiopurines, calcineurin-inhibitors, and TNFα-inhibitors, have been found to be effective in treating UGI UC. Only one other case report reported the successful use of adalimumab to attain remission in UGI UC.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;This review sheds light on a rare presentation of UC. This highlights the need for further research into the pathogenesis of UC and treatment strategies for patients presenting with UGI UC. Our case further strengthens the use","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"34 1","pages":"128-132"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143736271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}